Comparing iShares Pharma ETF and Invesco's Equal Weight Healthcare Fund

The iShares U.S. Pharmaceuticals ETF (IHE) and Invesco S&P 500 Equal Weight Health Care ETF (RSPH) are two popular exchange-traded funds (ETFs) that focus on the healthcare sector. While both funds have been around since 2006, they differ significantly in their construction and investment approach. In this article, we will delve into the key differences between these two ETFs and examine their performance over various time periods.

Construction and Investment Approach

The iShares U.S. Pharmaceuticals ETF (IHE) targets the pharmaceutical sub-sector using market-cap weighting, resulting in significant concentration in industry giants such as Johnson & Johnson (JNJ), Eli Lilly & Co (LLY), and Merck & Co (MRK). On the other hand, the Invesco S&P 500 Equal Weight Health Care ETF (RSPH) captures the entire S&P 500 healthcare sector, assigning roughly equal importance to each constituent. This equal-weighted approach avoids concentration risk often found in cap-weighted sector funds.

Performance Comparison

The performance of IHE and RSPH over various time periods is a crucial aspect to consider when deciding between these two ETFs. Over the past three years, IHE has beaten RSPH, returning 19.9% compared to RSPH's annualized three-year returns of 9.6%. Similarly, over the past five years, IHE has outperformed RSPH, returning 11.9% compared to RSPH's annualized five-year returns of 5.2%. However, over the past decade, RSPH has been the better-performing ETF, returning 9.8% to IHE's 9.3%.

Key Metrics and Holdings

A closer look at the key metrics and holdings of IHE and RSPH reveals some interesting differences. IHE has a slightly lower expense ratio of 0.37% compared to RSPH's 0.4%. Additionally, IHE has a higher dividend yield of 1.4% compared to RSPH's 0.6%. The largest positions in IHE include Johnson & Johnson (JNJ) at 22.5%, Eli Lilly & Co (LLY) at 20.5%, and Merck & Co (MRK) at 5%. On the other hand, RSPH's largest positions include Moderna Inc (MRNA) at 4.4%, Veeva Systems Inc (VEEV) at 2.5%, and Charles River Laboratories International (CRL) at 2.2%.

Conclusion

In conclusion, the iShares U.S. Pharmaceuticals ETF (IHE) and Invesco S&P 500 Equal Weight Health Care ETF (RSPH) are two distinct ETFs that cater to different investment approaches and risk tolerance. While IHE has outperformed RSPH over the past three and five years, RSPH has been the better-performing ETF over the past decade. Investors should carefully consider their investment goals, risk tolerance, and time horizon before making a decision between these two ETFs.

What to Watch Next

As the healthcare sector continues to evolve, it will be essential to monitor the performance of IHE and RSPH. Investors should keep a close eye on the fund's holdings, expense ratios, and dividend yields. Additionally, the impact of any changes in the S&P 500 healthcare sector on the performance of RSPH should be closely watched. By staying informed and adaptable, investors can make informed decisions and potentially reap the benefits of these two ETFs.